PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease

Review (24 studies [18 alirocumab; 6 evolocumab]; n=60,997) found strong evidence base to prescribe PCSK9 monoclonal antibodies to people who might not be eligible for other lipid‐lowering drugs, or to people who cannot meet their lipid goals on more traditional therapies.

Source:

Cochrane Database of Systematic Reviews